AstraZeneca has unveiled a 15 billion dollar investment plan in China, underscoring renewed commercial momentum between Beijing and London as the UK prime minister visits the country. The British Swedish pharmaceutical group said the investment, running through 2030, will expand medicines manufacturing and
Suzhou, a city long celebrated for its classical gardens, ancient canals and poetic landscapes, is rapidly reinventing itself as one of China’s most ambitious biotechnology hubs. Five years ago, local leaders laid out a daring plan: transform Suzhou into the “Pharma Valley of
Gene therapy, precision medicine, and biotech startups are Beijing’s next frontier industries. The Next Growth Engine China’s economic playbook is shifting. After decades of growth fueled by manufacturing and property, Beijing is betting on biotechnology as the next frontier industry. From gene therapies
